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Abstract
Background
Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) is
unknown. Therefore, we systematically reviewed the literature to compare results of open
surgical repair (OSR), standard thoracic endovascular aortic repair (TEVAR) or branched
and fenestrated TEVAR (BEVAR/FEVAR) for CBAD.
Methods
EMBASE and MEDLINE databases were searched for eligible studies between January
2000 and October 2015. Studies describing outcomes of OSR, TEVAR, B/FEVAR, or all, for
CBAD patients initially treated with medical therapy, were included. Primary endpoints were
early mortality, and one-year and five-year survival. Secondary endpoints included occur-
rence of complications. Furthermore, a Time until Treatment Equipoise (TUTE) graph was
constructed.
Results
Thirty-five articles were selected for systematic review. A total of 1081 OSR patients, 1397
TEVAR patients and 61 B/FEVAR patients were identified. Early mortality ranged from
5.6% to 21.0% for OSR, 0.0% to 13.7% for TEVAR, and 0.0% to 9.7% for B/FEVAR. For
OSR, one-year and five-year survival ranged 72.0%-92.0% and 53.0%-86.7%, respectively.
For TEVAR, one-year survival was 82.9%-100.0% and five-year survival 70.0%-88.9%. For
B/FEVAR only one-year survival was available, ranging between 76.4% and 100.0%. Most
common postoperative complications included stroke (OSR 0.0%-13.3%, TEVAR 0.0%-
11.8%), spinal cord ischemia (OSR 0.0%-16.4%, TEVAR 0.0%-12.5%, B/FEVAR 0.0%-
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12.9%) and acute renal failure (OSR 0.0%-33.3%, TEVAR 0.0%-34.4%, B/FEVAR 0.0%-
3.2%). Most common long-term complications after OSR included aneurysm formation
(5.8%-20.0%) and new type A dissection (1.7–2.2%). Early complications after TEVAR
included retrograde dissection (0.0%-7.1%), malperfusion (1.3%–9.4%), cardiac complica-
tions (0.0%–5.9%) and rupture (0.5%–5.0%). Most common long-term complications after
TEVAR were rupture (0.5%–7.1%), endoleaks (0.0%–15.8%) and cardiac complications
(5.9%-7.1%). No short-term aortic rupture or malperfusion was observed after B/FEVAR.
Long-term complications included malperfusion (6.5%) and endoleaks (0.0%-66.7%). Rein-
tervention rates after OSR, TEVAR and B/FEVAR were 5.8%-29.0%, 4.3%-47.4% and
0.0%-53.3%, respectively. TUTE for OSR was 2.7 years, for TEVAR 9.9 months and for B/
FEVAR 10.3 months.
Conclusion
We found a limited early survival benefit of standard TEVAR over OSR for CBAD. Compli-
cation rates after TEVAR are higher, but complications after OSR are usually more serious.
Initial experiences with B/FEVAR show its feasibility, but long-term results are needed to
compare it to OSR and standard TEVAR. We conclude that optimal treatment of CBAD
remains debatable and merits a patient specific decision. TUTE seems a feasible and useful
tool to better understand management outcomes of CBAD.
Introduction
Currently, the optimal management of chronic type B aortic dissections (CBAD) remains
undetermined as there have been no randomized controlled trials comparing open surgical
repair (OSR) and thoracic endovascular aortic repair (TEVAR) [1]. Furthermore, branched
and fenestrated TEVAR (B/FEVAR) are emerging as new techniques to treat more complicated
cases with an endovascular approach [2]. The initial treatment objective for uncomplicated
acute type B dissections is clinical stabilization of the patient through optimal medical therapy
(OMT) to prevent propagation of the dissection, malperfusion, rapid aortic dilatation and/or
rupture. However, secondary interventions after initial OMT are common, with intervention
rates ranging between 9.0% and 40.6% [3–14]. Most common indications for secondary inter-
ventions for CBAD include aneurysm formation, rapid aneurysmal sac enlargement, extension
of dissection and malperfusion [3–13, 15].
Both endovascular therapies and OSR show up- and downsides; endovascular management
is less invasive, however successful treatment during the chronic phase may be challenging due
to thickening of the intimal flap. Standard TEVAR for CBAD patients has shown acceptable
mid-term outcomes, however complete aortic remodeling was seen in only 36% of cases [16],
mostly precluded due to abdominal extension of the dissection. Such extended involvement
determines a thoracoabdominal aortic issue that may require a more extensive repair. In such a
setting, branched and fenestrated procedures may offer an endovascular solution. However,
anatomical limitations like narrow lumens and technical difficulties, such as the orientation of
the branches and fenestrations, and the presence of the lamella inside the lumen, make the pro-
cedure challenging. Nevertheless, in general, any type of endovascular management could be of
value in chronic patients, reducing operative risks of OSR. An open approach is more invasive
with higher operative risks [17], but unlike endovascular management, it is rarely affected by
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anatomical constraints. Currently, OSR is the most commonly adopted strategy, in particular
in younger patients and those affected by connective tissue disorders, while endovascular treat-
ment has been adopted for specific clinical scenarios such as limited extent of the dissection,
intramural hematoma evolving with penetrating aortic ulcer, and older patients. Our aim was
to systematically review the literature and compare outcomes of CBAD patients managed with
OSR, TEVAR and B/FEVAR, who were initially treated with OMT alone.
Materials and Methods
Search strategy
The EMBASE and MEDLINE databases were searched for eligible studies from January 1st,
2000 up to October 1st, 2015. The following search terms were used: ‘follow-up’, ‘chronic’,
‘post-dissection’ ‘type B’, ‘aortic/aorta dissection’ and ‘outcome’, or synonyms (S1 Appendix).
Article selection
The Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines were used
for analysis of the studies in this systematic review [18]. Included studies were critically
assessed for study design, heterogeneity, possible bias, and other limitations. Two reviewers
(AK and HB) performed eligibility for this systematic review independently. Disagreement
between reviewers was resolved during a consensus meeting. Inclusion criteria were: (1)
English language; (2) case series describing outcomes of OSR, TEVAR, B/FEVAR or multiple,
for CBAD; and (3) follow-up of at least one year. Exclusion criteria were: (1) studies before
2000 to ensure contemporary practice in all included studies; (2) patients initially treated with
invasive therapy; (3) case reports; (4) studies describing mixed populations without separate
outcomes listed; and (5) articles from the same institution or author were studied critically to
ensure no overlapping patient populations were included in the final analysis.
Extracted data and endpoints
Data extracted included demographics, patient history, intervention details, and follow-up out-
comes. The primary endpoints were early mortality, and one- and five-year survival. Secondary
endpoints included the occurrence of complications. Early outcomes were defined as either in-
hospital or 30-day outcome. Long-term outcomes were defined as occurring during follow-up.
Rapid aortic enlargement was defined as0.5 cm increase in diameter per year.
TUTE
The concept of “time until treatment equipoise” (TUTE) has been described in an attempt to
better and easier advise patients of relative risks of different management modalities [19]. It is
defined as the duration of time that elapses after an intervention, before the risk of the inter-
vention is canceled out and reversed by the cumulative risk of conservative management. In
other words, it is the point in time during follow-up after which an intervention is most benefi-
cial, because the mortality risk of the intervention is lower than the mortality risk of continuing
conservative management. TUTE may guide decision making for asymptomatic patients on
prognostic grounds. The equipoise is set at the point where the areas between the survival
curves of no intervention and intervention are equal. This point is chosen instead of the cross-
ing of the lines, because the intervention itself also carries operative mortality risk, which needs
to be accounted for. To estimate TUTE for OSR, TEVAR and B/FEVAR, we performed a
TUTE analysis as described by the creators of the concept [19]. In this analysis, the gender, age,
mortality rate for the intervention and the expected added mortality rate per year due to the
Contemporary Management Strategies for Chronic Type B Aortic Dissections: A Systematic Review
PLOSONE | DOI:10.1371/journal.pone.0154930 May 4, 2016 3 / 15
natural history of the condition, are entered. We used the mean age for each of the interven-
tions and the 30-day mortality rate for each intervention. The expected mortality without inter-
vention was adopted from recent available literature [20]. Based on these risk factors, survival
curves are calculated, and the point in time where the area between the two curves before and
after the crossing of the lines is equal (intervention vs. no intervention) is given. This is the
point in time after which an intervention improves survival compared to only medical manage-
ment, e.g. TUTE.
Statistical analysis
We discussed the end-points and our rationale for this study with our institutional statistical
center (Julius Support Center, UMC Utrecht, the Netherlands). After initial investigation of
available studies, it was concluded that a meta-analysis was not feasible and not advisable. This
decision was made because of the large heterogeneity among the available literature, since all
studies used different in- and exclusion criteria, diverse definitions, and reported different fol-
low-up times. Furthermore, in many studies the original data were not present.
Data are presented as mean ± SD or as percentage. Percentages per variable were calculated
by dividing the observed total by the combined total of patients from the studies reporting the
characteristic. Values of<0.05 were considered significant. Data analysis and graphing were
performed using Microsoft Excel (Microsoft Inc.) and SPSS (SPSS 22 Inc., Chicago, Ill, USA).
Results
Included studies
A total of 35 articles were selected for systematic review (Fig 1). The initial search of EMBASE
and MEDLINE provided 702 articles. After removal of duplicates, 579 articles remained. Of
these, 404 articles could be excluded based on the content of the abstract. Seventy-one full-text
articles were assessed more closely, after which another 40 articles were excluded. Thirty-one
articles were deemed eligible for this systematic review. Cross-referencing of the remaining
articles yielded four articles, leaving a final number of 35 articles. No qualitative analysis, e.g.
meta-analysis, was performed since the heterogeneity of included studies was large, and there-
fore a quantitative analysis was most suitable.
Patient characteristics
The OSR cohort comprised of 1081 patients, with a mean age of 58.2 ± 3.8 years [21–30]. The
reported follow-up for these studies ranged between 34 months and 102 months. Overall, there
were 816 males (74.2%) [21–31]. Demographic details and medical history of these patients are
listed in S1 Table.
The TEVAR cohort consisted of 1397 patients with a mean age of 59.4 ± 4.2 years and
76.0% was male (n = 1051) [21, 29, 32–52]. Follow-up ranged between 12 and 90 months. All
TEVAR patient characteristics are shown in S2 Table. Sixty-one B/FEVAR patients were
included, mean age 65.7 (± 8.0 years) [53, 54]. Follow-up ranged between 17 months and 20.4
months. Overall, 83.6% of patients were males. All other details are listed in S3 Table.
Interventional details
Several studies described the timing of OSR; elective interventions were performed between
53.2% and 95.7% [21–25, 30], while urgent and emergent interventions were performed
between 10.5% and 12.5% [21, 24], and 3.1% to 7.7% [21, 25, 30], respectively. The exact inter-
val between incident dissection and OSR was available in three studies, ranging between a
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mean of 32.4–61.0 months [29, 30] and a median of 31.0 (thoraco-abdominal extent) to 43.0
months (limited to descending aorta) [21]. Mean time to intervention was 35.5 months. For
37.4% of the patients the intervention was limited to the descending aorta [21–25, 29, 30],
while for the remaining patients the intervention was thoraco-abdominal [21–25, 27, 29, 30].
The operative details are reported in S1 Table.
For TEVAR, elective interventions ranged between 62.5% and 100.0% [21, 28, 38, 45, 46,
52], urgent operations between 18.8% and 97.2% [21, 28, 41], and emergency procedures were
performed between 2.0% and 18.8% [21, 28, 41, 43, 45, 46, 49, 51, 52]. Reported time intervals
from incident dissection to TEVAR ranged between a median of 3 weeks up to 36.0 months
[21, 34, 36, 44, 46] and a mean of 3 weeks and 53.8 months [29, 33, 37, 38, 40, 43, 45, 49, 50].
Mean time to intervention was 24.4 months. Indications for TEVAR were aortic aneurysm
(74.5% to 100.0%) [28, 32, 35, 37, 43, 45, 48, 49], failure of OMT (12.3%) [32], rupture (2.7% to
10.0%) [32, 35, 41, 43, 46, 49], rapid aortic enlargement (11.8% to 100.0%) [28, 37, 41, 43, 49],
recurrent/refractory pain (4.3% to 57.7%) [32, 37, 41, 43, 49], malperfusion (2.5% to 18.8%)
[32, 41, 46, 49], patent false lumen (FL) (64.2%) [40] and other indications (6.6% to 23.5%)
[37, 40, 49]. Double indications could be present in a single patient. Complete details are listed
in S2 Table.
Fig 1. Flowchart of article selection.
doi:10.1371/journal.pone.0154930.g001
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All B/FEVAR procedures were elective and the only reported indication for these proce-
dures was aneurysmal degeneration [53, 54]. Reported time from incident dissection to the
intervention was noted in one study and was 31.0 months [54]. Technical success was achieved
in 93.5% in one case series [54] and 100.0% in another study [53]. Complete details are listed in
S3 Table.
Survival
Short-term mortality after OSR ranged between 5.6% and 21.0% [21–30]. One-, five- and ten-
year survival was between 72.0% and 92.0% [21, 23, 24, 27, 28, 30], 53.0% and 86.7% [22–25,
27, 29], and between 32.0% and 60.0% [23, 25, 27], respectively. One study reported a 15-year
survival of 49.0% [25] (Table 1).
For TEVAR, early mortality was reported to be between 0.0% and 13.7% [21, 28, 29, 32–52].
One-year survival was between 82.9% and 100.0% [21, 28, 32, 35, 37, 40, 41, 43, 47]. Five-year
survival was between 64.0% and 88.9% [29, 40, 41, 43, 45, 47, 50, 52]. Ten-year survival was
reported in one study, with a survival rate of 63.0% [40] (Table 2). One-year dissection-related
survival was 97.1% in one study [41] and five-year dissection-related survival ranged between
92.1% and 98.3% [39, 41, 45, 52].
Table 1. Complications and survival OSR.
Andersen
2014[21]
Bashir
2014
[22]
van
Bogerijen
2015[29]
Conrad
2011
[23]
Conway
2014[24]
Estrera
2015
[25]
Fujikawa
2015 [30]
Goksel
2008
[26]
Kouchoukos
2015[27]
Nozdrzykowski
2013[28]
Saﬁ
2002
[31]
ST Stroke 5 (15.6) 7 (11.3) 1 (1.1) 2 (2.7) 2 (2.3) 5 (2.4) 7 (3.0) 0 2 (2.9) 2 (13.3) NR
ST SCI 3 (9.4) 2 (3.2) 4 (4.4) 12
(16.4)
2 (2.3) NR 14 (6.0) 0 4 (5.8) 2 (13.3) 7
(3.6)
ST ARF 3 (9.4) 16
(26.0)
7 (7.8) 8 (11.0) 2 (2.3) 21
(10.0)
24 (10.2) 0 3 (4.3) 5 (33.3) NR
ST MI NR NR NR 10
(14.0)
NR NR 9 (3.8) 0 2 (2.9) NR NR
FU Rupture NR NR NR NR NR NR 1 (0.4) 0 NR NR NR
FU
Malperfusion
NR NR NR NR NR NR NR 0 NR NR NR
FU
aneurysm
formation
NR NR 6 (6.7) NR 5 (5.8) NR NR 3 (20.0) NR NR NR
FU new type
A dissection
NR NR 2 (2.2) NR NR NR 4 (1.7) NR NR NR NR
Reoperation 4 (12.5) 7 (11.3) 10 (11.1) NR 5 (5.8) NR 31 (13.0) 3 (20.0) 20 (29.0) 5 (33.3) NR
ST mortality 2 (6.3) 13
(21.0)
5 (5.6) 8 (11.0) 5 (5.8) 18
(18.6)
20 (8.5) 2 (13.3) 4 (5.8) 2 (13.3) NR
1-year
survival
88.0 NR NR 72.0 92.0 NR 87.6 NR 86.6 73.3 NR
3-y survival NR NR NR NR NR NR 86.5 NR NR 73.3 NR
5-year
survival
NR 72.6 86.7 53.0 83.0 72.0 NR NR 65.0 NR NR
7-year
survival
NR NR NR NR 70.0 NR NR NR NR NR NR
10-year
survival
NR NR NR 32.0 NR 60.0 NR NR 40.0 NR NR
ARF = acute renal failure; FU = follow-up; MI = myocardial infarction; OSR = open surgical repair; SCI = spinal cord ischemia; ST = short term
doi:10.1371/journal.pone.0154930.t001
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Early mortality after B/FEVAR ranged between 0.0% and 9.7% [53, 54]. One-year survival
was between 76.4% and 100.0% [53, 54]. Five-year survival was not available in these studies.
Two- and three-year survival was noted in one study, being 85.0%-100.0% and 75.0%-85.0%,
respectively [53]. All details can be found in Table 3.
Three studies reported outcomes for both OSR and TEVAR. These studies might be of most
predictive value and most informative, since they compared both interventions using a similar
population of patients. No differences were reported for one-year survival between OSR and
TEVAR [21, 28], as well as for five-year survival (p-value 0.23) [29].
Complications
For OSR, the most common early complications were stroke (0.0% and 13.3%) [21–30], spinal
cord ischemia 0.0%-16.4%) [21–24, 26–31] and acute renal failure (0.0% -33.3%). Long-term
complications after OSR included aneurysm formation (5.8%-20.0%) [24, 26, 29] and new type
A dissection (1.7–2.2%) [29, 30]. Complete results are shown in Table 1.
Most common early complications after TEVAR included stroke (0.0%–11.8%) [21, 28, 29,
32–36, 38–40, 42–45, 47, 49, 51, 52], spinal cord ischemia (0.0%–12.5%) [21, 28, 29, 32–36, 40,
42–47, 52] and acute renal failure (0.0%–34.4%) [3, 21, 28, 29, 33–35, 39, 40, 42, 43, 45–47, 49–
51]. Endoleaks (0.0%–15.8%) [21, 28, 29, 32–39, 41, 44, 45, 50–52] were common during fol-
low-up. Other late or long-term complications included rupture (0.5%–7.1%) [28, 34–36, 40,
41, 52], malperfusion (0.0%–3.6%) [33, 37, 38, 52] and cardiac complications (5.9%-7.1%) [34,
49]. All results are listed in Table 2.
Early complications after B/FEVAR included spinal cord ischemia (0.0%-12.9%) [21, 28, 29,
32–36, 40, 42–47, 52–54], acute renal failure (0.0%–3.2%) [53, 54], and cardiac complications
(3.2%) [54]. Late complications included malperfusion (0.0%–6.5%) and endoleaks (0.0%–
66.7%) [53, 54]. All results are listed in Table 3.
Reinterventions
Reoperations after OSR were common, ranging between 5.8% and 29.0% (Table 1) [21, 22, 24,
26–30]. Most reinterventions after OSR were managed with another open repair; only in a
small number of cases an endovascular procedure was performed [21, 22, 24, 26–30]. Reasons
for reintervention included retrograde dissection [29], bleeding [22], aneurysm formation [24,
29] and renal failure [29]. One study described mortality after the reintervention (30.0%). Indi-
cations for these procedures were graft infection, thoraco-abdominal aneurysm and aneurys-
mal growth of distal dissection. Procedures performed were TEVAR (n = 2) and hybrid (n = 1)
[29].
For TEVAR, reinterventions were reported between 4.3% and 47.4% (Table 2) [21, 28, 29,
32, 34, 36, 37, 39, 41, 43–47, 49, 50, 52]. Reported reinterventions were TEVAR (58.9%), OSR
(27.0%), embolization/ballooning (8.0%) or other (6.1%). Common reasons for reintervention
included endoleak [21, 29, 32, 36, 37, 39, 44–46, 50, 52], aneurysm formation [21, 34, 37, 46,
49, 52], retrograde dissection [21, 29, 37, 46, 49, 52], distal FL perfusion [21, 32, 44, 49, 52],
rupture [34, 36, 52], and malperfusion syndromes [52]. Only a few studies described outcomes
after secondary intervention: Andacheh et al. reported no mortality [32], while van Bogerijen
reported two deaths due to type III endoleaks (40.0%) [29]. Jia et al. reported a mortality of
66.6% after secondary intervention; reasons for mortality were multi-organ failure (n = 1), type
A dissection (n = 1) and unknown (n = 4) [36]. Lastly, Nathan et al. reported one death after
open surgical reintervention (11.1%) [43].
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Reinterventions after B/FEVAR were between 0.0% and 53.3% (Table 3) [53, 54]. Reported
reinterventions were all endovascular, always for treating endoleaks. Only one study described
outcomes after secondary intervention, with no observed mortality [54].
Time until Treatment Equipoise (TUTE)
The following parameters were entered in the TUTE analysis for each intervention: OSR
(Male, 58 years, intervention mortality 9.9%, no intervention mortality 7.5%), TEVAR (male,
59 years, mortality intervention 3.1%, no intervention mortality 7.5%), and B/FEVAR (male,
65 years, mortality intervention 3.2%, no intervention mortality 7.5%). This resulted in TUTE
for OSR of 2.7 years, for regular TEVAR this was 9.9 months and for B/FEVAR 10.3 months
(Fig 2). This suggests TEVAR is the treatment that will have the earliest beneficial impact, com-
pared to OSR and B/FEVAR. This is because TEVAR has lower operative risks compared to
OSR. The available results of B/FEVAR are limited in current literature, making comparison
vulnerable to bias. However, B/FEVAR seems to become more beneficial than just medical
management after a similar timeframe as standard TEVAR, about 9–10 months after the inci-
dent dissection.
Discussion
In this systematic review, short and long-term mortality rates of TEVAR for CBAD seemed to
be favorable compared to those managed with OSR. To actually compare the results of B/
FEVAR to the other two intervention strategies is challenging because of the small number of
studies available. Most complications were observed after TEVAR, mainly related to the stent-
graft, such as endoleak, rupture, and malperfusion. Although more reinterventions were
Table 2. Complications and survival TEVAR.
Andacheh
2012[32]
Andersen
2014[21]
van
Bogerijen
2015[29]
Chen
2013
[33]
Czerny
2010
[34]
Guangqi
2009[35]
Jia
2013
[36]
Kang
2011[37]
Kato
2002
[38]
Kim
2009
[39]
Kitamura
2014[40]
Lee
2013[41]
TEVAR 73 44 32 56 14 49 208 76 14 72 53 71
ST Stroke 1 (1.4) 0 1 (3.1) 3 (5.4) 0 1 (2.0) 0 NR 0 0 2 (3.8) NR
ST SCI 1 (1.4) 0 0 0 0 0 2 (1.0) NR NR NR 0 NR
ST ARF NR 1 (2.3) 1 (3.1) 4 (7.1) 0 0 NR NR NR 1 (1.4) 1 (1.9) NR
ST retro diss 4 (5.5) NR NR 1 (1.8) 0 NR 2 (1.0) 1 (1.3) NR NR NR NR
ST malperfusion NR NR NR NR NR NR NR NR NR NR NR NR
ST cardiac complications 4 (5.5) NR NR NR 1 (7.1) NR 2 (1.0) NR NR NR NR NR
ST rupture 2 (2.7) NR NR NR NR NR NR NR NR NR NR NR
FU Rupture NR NR NR NR 1 (7.1) 1 (2.0) 6 (2.9) NR NR NR 2 (3.8) 1 (1.4)
FU Malperfusion NR NR NR 2 (3.6) NR NR NR 1 (1.3) 0 NR NR NR
FU Endoleak 7 (9.6) 2 (4.5) 4 (12.5) 1 (1.8) 2 (14.3) 5 (10.2) 3 (1.4) 5 (6.6) 0 6 (8.3) NR 1 (1.4)
FU cardiac compl NR NR NR NR NR NR NR NR NR NR NR NR
Stent collapse/migration NR 1 (2.3) NR NR NR NR NR 3 (3.9) NR NR NR 2 (2.8)
Reoperation 11 (15.1) 14 (31.8) 5 (15.6) NR 2 (14.3) NR 9 (4.3) 19 (25.0) NR 9 (12.5) NR 25 (35.2)
ST mortality 10 (13.7) 0 0 0 0 4 (8.2) 0 4 (5.3) 0 0 0 1 (1.4)
1-year survival 86.0 90.0 NR NR NR 82.9 NR 86.0 NR NR 100.0 97.1
1-y aorta survival NR NR NR NR NR NR NR NR NR NR NR 97.1
5- year survival NR NR 78.1 NR NR NR NR NR NR NR 86.0 88.9
5-year aorta survival NR NR NR NR NR NR NR NR NR 98.3 NR 92.1
10-y survival NR NR NR NR NR NR NR NR NR NR 63.0 NR
(Continued)
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required after TEVAR, the type of procedure was usually less invasive. A large percentage
(>60.0%) of the reinterventions was represented by another endovascular procedure, an embo-
lization or a ballooning of the stent-graft. Complications following OSR were usually more
severe and the subsequent reintervention was frequently another open procedure. Complica-
tion rates after B/FEVAR were generally low, usually represented by endoleaks, and reinterven-
tion rates were high, always endovascular.
Our results show that it is difficult to distinguish which intervention is most suitable for
CBAD. Currently, no randomized controlled clinical trials exist, mainly due to the rarity of the
disease, to provide definitive evidence on optimal management strategy for CBAD. Therefore,
comparison of observational data of these management modalities is important.
Actually, management of complicated acute and subacute type B dissection is usually per-
formed by TEVAR while OSR is reserved for those patients affected by connective tissue disor-
ders or with unsuitable anatomy for endovascular approach [1]. For CBAD patients this choice
is more challenging, because other factors play a role in decision-making. In the chronic phase
the TL is often small due to chronic compression of the lumen and scarring and thickening of
the intimal flap occurs. Therefore, TL expansion and aortic remodeling is more challenging to
accomplish when compared to treatment in the acute phase [1]. Moreover, the frequent
involvement of the abdominal aorta in type B dissection explains why TEVAR for chronic dis-
sections, although liberally used, is associated with high reintervention rates.
OSR is often used as the treatment of choice for CBAD, especially for extensive dissections
involving visceral arteries and for patients that are deemed unsuitable for TEVAR. Besides sev-
eral technical problems, as mentioned above, short landing zones or strong angulation in the
arch could inhibit the use of endovascular techniques.
Melissano
2008[42]
Nathan
2015[43]
Nozdrzykowski
2013[28]
Oberhuber
2011[44]
Parsa
2011[45]
Patterson
2013[52]
Sayer
2008[46]
Scali
2013[47]
Shimono
2002[48]
Song
2006[49]
Xu
2010
[50]
Yang
2012[51]
11 47 32 19 51 196 40 80 13 17 84 28
0 2 (4.3) 1 (3.1) 0 0 4 (2.1) NR 8 (10.0) NR 2 (11.8) NR 1 (3.6)
0 3 (6.4) 3 (9.3) 2 (10.5) 0 6 (3.1) 0 10 (12.5) NR NR NR NR
1 (9.1) 3 (6.4) 11 (34.4) NR 1 (2.0) NR 0 1 (1.3) NR 1 (5.9) 2 (2.4) 2 (7.1)
0 0 NR NR 2 (3.9) NR 1 (2.5) NR NR 1 (5.9) 1 (1.2) 2 (7.1)
NR 1 (2.1) 3 (9.4) NR NR NR NR 1 (1.3) NR NR NR 1 (3.6)
0 NR NR NR NR NR NR 3 (3.8) NR 1 (5.9) NR NR
NR 1 (2.1) NR NR NR 1 (0.5) 2 (5.0) NR NR NR NR NR
NR NR 2 (6.3) NR NR 1 (0.5) NR NR NR NR NR NR
NR NR NR NR NR 7 (3.6) NR NR NR NR NR NR
NR NR 2 (6.3) 3 (15.8) 2 (3.9) 12 (6.1) NR NR NR NR 7 (8.3) 4 (14.3)
NR NR NR NR NR NR NR NR NR 1 (5.9) NR NR
NR NR 1 (3.1) NR NR NR NR NR NR NR NR NR
NR 9 (19.1) 9 (28.1) 9 (47.4) 5 (9.8) 34 (17.4) 6 (15.0) 23 (28.8) NR 3 (17.6) 3 (3.6) NR
0 2 (4.3) 2 (6.3) 0 0 8 (4.1) 3 2 0 2 1 2
NR 91.5 87.5 NR NR NR NR 89.0 NR NR NR NR
NR NR NR NR NR NR NR NR NR NR NR NR
NR 89.0 NR NR 77.0 64.0 NR 70.0 NR NR 84.4 NR
NR NR NR NR 98.0 96.0 NR NR NR NR NR NR
NR NR NR NR NR NR NR NR NR NR NR NR
ARF = acute renal failure; FU = follow-up; MI = myocardial infarction; SCI = spinal cord ischemia; ST = short term; TEVAR = thoracic endovascular aortic
repair
doi:10.1371/journal.pone.0154930.t002
Table 2. (Continued)
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B/FEVAR allow for treatment of more challenging cases by endovascular means. This novel
technique has been reported in highly selected cases in limited expert centers because of chal-
lenging issues related to narrow lumens, correct orientation of branches and fenestrations, and
diminished sealing capacity in such setting. Because of limited reporting on B/FEVAR, it is dif-
ficult to compare it to standard TEVAR and OSR, and additional and long-term results are
highly anticipated.
TUTE has been recently introduced to educate patients, but also to determine appropriate
timing of an intervention[19]. Our analysis showed that the TUTE for regular TEVAR was 9.9
months, 10.3 months for B/FEVAR, and 2.7 years for OSR. Such results are in agreement with
the increasing CBAD standard TEVAR management. The reason lies in the lower operative
risk compared to OSR, associated with a relevant percentage of positive outcomes, despite
higher rates of reintervention.
This systematic review has several limitations; first, we did not perform qualitative analyses.
After careful consideration with our affiliated statistical center (Julius Support Center, UMC
Utrecht, The Netherlands), it was considered to be not feasible and advisable to perform a
meta-analysis. The heterogeneity among the data was too large, since all studies used different
in- and exclusion criteria, diverse definitions, and reported different follow-up times. Further-
more, in many studies the original data were not present. Another limitation is that the rate of
elective or urgent/emergent interventions differed fundamentally between studies, and a large
number of studies did not report any procedural details. This might have caused differences in
occurrence of complications and mortality.
Table 3. Complications and survival B/FEVAR.
Kitagawa 2013a [53] Kitagawa 2013b [53] Oikonomou 2014 [54]
B/FEVAR 15 15 31
ST Stroke 0 0 0
ST SCI 0 0 4 (12.9)
ST ARF 0 0 1 (3.2)
ST retro diss NR NR NR
ST malperfusion 0 0 0
ST cardiac complications NR NR 1 (3.2)
ST rupture 0 0 0
FU Rupture 0 0 0
FU Malperfusion 0 0 2 (6.5)
FU Endoleak 10 (66.7) 0 12 (38.7)
FU cardiac compl NR NR NR
Stent collapse/migration NR NR NR
Reoperation 8 (53.3) 0 7 (22.6)
ST mortality 0 0 2 (9.7)
1-year survival 85.0 100.0 76.4
2-year survival 85.0 100.0 NR
3-year survival 85.0 75.0 NR
ARF = acute renal failure; B/FEVAR = branched and fenestrated thoracic endovascular aortic repair;
FU = follow-up; MI = myocardial infarction; SCI = spinal cord ischemia; ST = short term
a Extensive dissection cohort (Type II/III)
b Focal dissection cohort (without visceral involvement)
doi:10.1371/journal.pone.0154930.t003
Contemporary Management Strategies for Chronic Type B Aortic Dissections: A Systematic Review
PLOSONE | DOI:10.1371/journal.pone.0154930 May 4, 2016 10 / 15
Conclusion
In conclusion, this systematic review suggests a limited early survival benefit of standard
TEVAR over OSR for CBAD. The complication rates after TEVAR are higher, but the
Fig 2. Time until Treatment Equipoise. Results of TUTE analysis for OSR (top), TEVAR (middle) and B/
FEVAR (bottom) for CBAD.
doi:10.1371/journal.pone.0154930.g002
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complications after OSR are usually more serious. Initial experiences with B/FEVAR show that
this is a safe and feasible approach but long-term results are needed to compare it to OSR and
standard TEVAR. Nevertheless, further development of dedicated branched and fenestrated
stent-grafts for CBAD is needed to continuously improve their performance and broaden its
indications. Until then, optimal treatment of CBAD remains debatable and merits a patient
specific decision based on anatomy, life expectancy, general patient condition, and available
expertise. TUTE seems a feasible and useful tool to better understand management outcomes
of CBAD.
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